Interim report 2025/2026
Filed with HKEX · Stock code 1406 · · 45 pages · English
Summary by 6ix AI
The report highlights a decrease in revenue compared to the previous year, alongside a significant loss for the period, attributed to ongoing governance issues and increased legal expenses. Despite these challenges, the company remains focused on maintaining service quality and optimizing costs while aiming to resolve outstanding governance matters. The report also includes a breakdown of revenue sources, with refractive treatments being the largest contributor, although this segment saw a decline in revenue.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clarity Medical Group Holding Limited on 6ix
Earlier from Clarity Medical
- Annual Report 2025
- Supplemental announcement in relation to the appointment of executive director
- Appointment of executive director
- Interim results for the six months ended 30 September 2025
- Annual results for the year ended 31 March 2026
Later from Clarity Medical
- Annual Report 2026
- Notification of Publication of Corporate Communication and Change Request Form to Registered Shareholders
- Notification of Publication of Corporate Communication and Request Form to Non-Registered Shareholders
- Nomination Committee Terms of Reference
- List of Directors and their Roles and Functions
Follow Clarity Medical into a list and get an email when it puts out news.
Follow Clarity Medical